drugset / Trial / NCT06399315

Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers

NCT06399315

Phase 1 Completed 112 enrolled Lomond Therapeutics Holdings, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

This is a clinical study aiming to assess pharmacokinetics and biomarker evidence of ZE46-0134 efficacy in Healthy Volunteers after single and multiple daily doses of the study drug

Timeline

Start
2023-07-28
Primary completion
2025-06-30
Completion
2025-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg
Subject Rabeprazole Small molecule 20 mg Oral
Subject ZE46-0134 Unknown Oral